PolyNovo to launch its NovoSorb BTM tech in European market at MEDICA

PolyNovo – a UK medical devices company specialising in the development of surgical solutions using the patented polymer technology NovoSorb – will be joining the ABHI UK Pavilion at MEDICA 2021 to launch its NovoSorb BTM (Biodegradable Temporising Matrix) technology into the European market.

Founded in 2004, PolyNovo aims to empower clinicians to improve patient outcomes through the development of pioneering surgical solutions. The company’s patented NovoSorb polymer technology was developed to fulfil the need for a synthetic biodegradable product that could be safely used in medical devices. NovoSorb BTM is the company’s first medical device using this technology. The device – a unique synthetic dermal scaffold used to treat complex wounds and burns where there has been a significant loss of tissue – was invented and developed by PolyNovo using polymer technology originating from CSIRO (Commonwealth Science Industry Research Organisation).

NovoSorb BTM – PolyNovo’s first product to be commercialised – is available for use in many countries. The device was granted CE mark approval for sale throughout UK/Ireland and the European Union at the end of 2019. The company is now looking to expand its footprint across Europe by exhibiting on the ABHI UK Pavilion at MEDICA 2021, where it will be launching a new smaller size of the device, which is indicated for diabetic foot ulcers and venous leg ulcers.

PolyNovo’s managing director, Paul Brennan, said: “We were thrilled to announce our expansion into Europe in 2020, and following the travel restrictions this past year this is the first chance we will have to exhibit the unique BTM dermal template to a wider audience. We are delighted for the opportunity to demonstrate our innovation within the globally trusted ABHI brand at MEDICA 2021 and look forward to connecting with new distributors to extend its benefits to more patients across Europe and worldwide. Our vision is always to support improved patient care using the power of our disruptive NovoSorb technology in the treatment of complex wounds.”

When trauma to the skin occurs, large portions of the surface of the skin (epidermis) and its deeper layers (dermis) are destroyed. PolyNovo’s novel BTM technology – a revolutionary biodegradable temporising matrix – is designed to temporarily close the wound and aid the body in generating new tissue. It works by compartmentalising a large wound into a series of interconnected microwounds, thus making it easier for the body to heal.

BTM can be utilised for full thickness and deep dermal wounds including traumatic injuries, burns, necrotising soft tissue infections and chronic wounds. It enables the generation of a vascularised neodermis which provides a more robust foundation for wound reconstruction than grafting alone. The device is also designed to limit wound scarring and contracture, providing an alternative option to lengthy, complex free-flap surgery. In addition, the technology is uniquely comprised of synthetic material, thus it does not contain any food for bacteria and has shown to be robust in the presence of infection.

Paul Benton, managing director, International at the ABHI added: “We are delighted that PolyNovo has chosen to launch their pioneering technology on the ABHI Pavilion. As a company they embody the power of innovation and its importance within healthcare, and we look forward to supporting them in their goals to expand and bring the benefits of their revolutionary device to more patients globally.”

MEDICA is taking place from 15 – 18 November 2021 and throughout the show, PolyNovo UK will be located on the ABHI UK Pavilion - Hall 16 Stand K42.